Nanmo Biotech (688265.SH) issued a pre-reduction. The net profit for the first half year is expected to be 8 million yuan to 10 million yuan, a year-on-year decrease of 44.96% to 55.97%

According to Zhitong Finance App News, Nanmo Biotech (688265.SH) released its 2026 semi-annual performance forecast. The company expects to achieve net profit of 8 million yuan to 10 million yuan in the half-year 2026, a year-on-year decrease of 44.96% to 55.97%. Net profit attributable to owners of the parent company is expected to be 13 million yuan to 15.8 million yuan for the semi-year 2026 after deducting the impact of share payments, an increase of 47.27% to 78.99% over the previous year.

Demand in the biomedical industry improved during the reporting period, and the company's revenue achieved steady growth compared to the same period last year. Affected by the company's implementation of the restricted stock incentive plan and employee stock ownership plan, the share payment fee for the current period increased significantly compared to the same period in 2025; at the same time, the share payment amount was reduced accordingly due to the limited stock incentive plan not meeting the expected performance standards. The combination of two factors led to a decrease in net profit attributable to owners of the parent company in the current period compared to the same period last year. Excluding the impact of share payments, the company achieved a significant increase in net profit attributable to owners of the parent company compared to the same period last year, mainly due to two aspects: first, a steady increase in revenue; second, the company continued to strengthen cost control and improve operational efficiency through measures such as optimizing cage layout, strictly controlling procurement costs, and improving cage usage efficiency, and overall gross margin increased year-on-year.